



## **Splice Bio awarded with a “RETOS de Colaboración” grant**

BARCELONA, October 20, 2020 – Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has been awarded a “RETOS-Colaboración” grant from the Spanish Ministry of Science and Innovation (RTC2019-006879-1).

Splice Bio leads the the consortium that includes the participation of Universitat Autònoma de Barcelona and Universitat Pompeu Fabra as partners. The consortium will work towards the development of new gene therapies.

### **About Splice Bio**

Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company has developed a proprietary, 3<sup>rd</sup>-generation intein platform that addresses two existing limitations of adeno-associated viruses (AAVs) as vectors for gene therapy, both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. The company is backed by Ysios Capital, Asabys Partners and Caixa Capital Risc. For additional information, visit [www.splice.bio](http://www.splice.bio).